TRex Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	-	-	39.11
Revenue Growth	-	-	-
Gross Profit	-	-	39.11
Selling, General & Admin	8.77	8.04	6.5
Research & Development	40.87	29.81	34.99
Operating Expenses	49.64	37.85	41.49
Operating Income	-49.64	-37.85	-2.38
Interest & Investment Income	3.34	3.15	2.01
Other Non Operating Income (Expenses)	-0.01	-0.07	-0.07
Pretax Income	-46.3	-34.76	-0.44
Income Tax Expense	0.09	0.05	2.7
Net Income	-46.39	-34.81	-3.14
Preferred Dividends & Other Adjustments	-	-	5.75
Net Income to Common	-46.39	-34.81	-8.89
Net Income Growth	-	-	-
Shares Outstanding (Basic)	4	4	4
Shares Outstanding (Diluted)	4	4	4
Shares Change	-	5.23%	-
EPS (Basic)	-10.48	-8.59	-2.31
EPS (Diluted)	-10.48	-8.59	-2.31
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-46.31	-41.43	-25.65
Free Cash Flow Per Share	-10.46	-10.22	-6.66
Gross Margin	-	-	100.00%
Operating Margin	-	-	-6.09%
Profit Margin	-	-	-22.73%
Free Cash Flow Margin	-	-	-65.59%
EBITDA	-49.41	-37.63	-1.12
EBITDA Margin	-	-	-2.87%
D&A For EBITDA	0.23	0.22	1.26
EBIT	-49.64	-37.85	-2.38
EBIT Margin	-	-	-6.09%

SEC Filings: 10-K · 10-Q